Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Ov��ari��ek Tanja) .

171 - 180 / 386
Na začetekNa prejšnjo stran14151617181920212223Na naslednjo stranNa konec
171.
Kako premagati izgubo las
Marija Velepič, Jožica Bostič-Pavlovič, Helena Drolc, Tanja Čufer, 1993, druge monografije in druga zaključena dela

Ključne besede: rak (medicina), bolniki, kemoterapija, radioterapija, izpadanje las, nasveti
Objavljeno v DiRROS: 29.04.2021; Ogledov: 1033; Prenosov: 324
.pdf Celotno besedilo (3,38 MB)

172.
Kako olajšamo težave ob zdravljenju s kemoterapijo
Marija Velepič, Jožica Bostič-Pavlovič, Helena Drolc, Tanja Čufer, 1993, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid

Ključne besede: rak (medicina), kemoterapija, bolniki, nasveti
Objavljeno v DiRROS: 29.04.2021; Ogledov: 1000; Prenosov: 315
.pdf Celotno besedilo (2,68 MB)

173.
174.
175.
Pot za uvajanje novih organiziranih presejalnih programov na državni ravni
Urška Ivanuš, Branko Zakotnik, Tanja Mate, Tina Bregant, 2020, objavljeni strokovni prispevek na konferenci

Ključne besede: onkologija, presejalni programi, javno zdravstvo, obvladovanje raka
Objavljeno v DiRROS: 08.04.2021; Ogledov: 963; Prenosov: 287
.pdf Celotno besedilo (83,93 KB)

176.
Pogled onkologa
Tanja Ovčariček, 2020, samostojni strokovni sestavek ali poglavje v monografski publikaciji

Ključne besede: onkologija, nefrologija, protitrombotično zdravljenje
Objavljeno v DiRROS: 06.04.2021; Ogledov: 979; Prenosov: 276
.pdf Celotno besedilo (40,61 KB)

177.
Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma : an international multicenter study
Luka Brčić, Thomas Klikovits, Zsolt Megyesfalvi, Berta Mosleh, Katharina Sinn, Richard Hritcu, Viktoria Laszlo, Tanja Čufer, Aleš Rozman, Izidor Kern, Katja Mohorčič, 2021, izvirni znanstveni članek

Povzetek: Background: Programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) immune-checkpoint blockade is a promising new therapeutic strategy in cancer. However, expression patterns and prognostic significance of PD-L1 and PD-1 are still controversial in human malignant pleural mesothelioma (MPM). Methods: Formalin-fixed paraffin-embedded (FFPE) tumor samples from 203 MPM patients receiving standard treatment without immunotherapy were collected from 5 European centers. PD-L1 and PD-1 expression of tumor cells (TCs) and tumor-infiltrating lymphocytes (TILs) were measured by immunohistochemistry and correlated with clinical parameters and long-term outcome. Results: High (>10%) PD-L1 TC and PD-1 TILs expressions were found in 18 (8%) and 39 (24%) patients, respectively. PD-L1 was rarely expressed by TILs [>/=1%, n=13 (8%); >10%, n=1]. No significant associations were found between the PD-L1 or PD-1 expression of TCs or TILs and clinicopathological parameters such as stage or histological subtype. Notably, patients with high (>10%) TC-specific PD-L1 expression exhibited significantly worse median overall survival (OS) (6.3 vs. 15.1 months of those with low TC PD-L1 expression; HR: 2.51, P<0.001). In multivariate cox regression analysis adjusted for clinical parameters, high TC PD-L1 expression (>10%) proved to be an independent negative prognostic factor for OS (HR: 2.486, P=0.005). There was no significant correlation between PD-L1 or PD-1 expression of TILs and OS. Conclusions: In this multicenter cohort study, we demonstrate that high (>10%) PD-L1 expression of TCs independently predicts worse OS in MPM. Further studies are warranted to investigate the value of PD-L1/PD-1 expression as a marker for treatment response in MPM patients receiving immunotherapy.
Ključne besede: mesothelioma - anatomy and histology - analysis, 1malignant pleural mesothelioma, programmed death-ligand 1, programmed cell death 1, PD-L1
Objavljeno v DiRROS: 31.03.2021; Ogledov: 1278; Prenosov: 548
URL Povezava na datoteko

178.
Pogledi bolnikov in onkologov na uvajanje telemedicine v času epidemije covid-19
Miha Oražem, Irena Oblak, Tanja Španić, Ivica Ratoša, 2020, izvirni znanstveni članek

Povzetek: Izhodišča: Pandemija koronavirusne bolezni 2019 (covid-19) je zaradi epidemioloških ukrepov, zlasti spodbujanja fizične distance, marsikje po svetu pospešila uvajanje telemedicine v klinično prakso. Zato smo želeli pridobiti stališča onkoloških bolnikov in zdravnikov do tovrstne obravnave v onkologiji. Metode: K izpolnjevanju dveh ločenih kvantitativnih vprašal-nikov smo med 27. majem in 11. junijem 2020 prek elektronske pošte ter s pomočjo Slovenskega združenja organizacij bolnikov z rakom (ONKO NET) povabili bolnike z rakom, ki so bili bodisi na aktivnem zdravljenju bodisi na sledenju po zaključenem zdravljenju, in zdravnike onkologe. Dodatno je bil v Sektorju radioterapije Onkološkega inštituta Ljubljana izveden presečni dan za bolnike med obsevanjem. Rezultati: Na spletni ali natisnjen vprašalnik za bolnike je odgovorilo 475 bolnikov, od tega 310 (65,3 %) na aktivnem onko-loškem zdravljenju in 132 (27,8 %) v fazi sledenja. Skoraj polovica bolnikov (48,4 %) je kot primarno diagnozo navedla rak dojk. Več kot desetina vseh (11,3 %) je zaradi pandemije želela opustiti zdravniški pregled. V zasebnem življenju jih pametni telefon ali tablico uporablja 72,4 % in vsaj 30 % bolnikov bi bilo pripravlje-nih v bodoče pogosteje uporabljati telemedicinske storitve. Od 168 povabljenih zdravnikov jih je na vprašalnik odgovoril 101 (60 %) in ocenil, da bi s pomočjo telemedicine lahko opravil 21 % (0%80 %) vseh svojih storitev. Če bi se sami znašli v vlogi bolnika, bi bila prip-ravljena po telemedicini poseči dobra polovica sodelujočih (54,5 %). Zaključki: Uporaba telemedicine v onkologiji bi bila ob upošteva-nju nekaterih omejitev sprejemljiva za pomemben del bolnikov in zdravnikov
Ključne besede: telemedicina, covid-19, onkologija
Objavljeno v DiRROS: 18.03.2021; Ogledov: 1610; Prenosov: 434
.pdf Celotno besedilo (272,20 KB)

179.
180.
Nrf2-interacting nutrients and COVID-19 : time for research to develop adaptation strategies
Jean Bousquet, Jean-Paul Cristol, Wienczyslawa Czarlewski, Josep M. Antò i Boquè, Adrian Martineau, Tari Haahtela, Susana C. Fonseca, Guido Iaccarino, Hubert Blain, Alessandro Fiocchi, Nisera Bajrović, Natalija Edelbaher, Maja Jošt, Peter Kopač, Anja Koren, Mitja Košnik, Karmen Kramer Vrščaj, Samo Kreft, Nika Lalek, Bojan Madjar, Tonka Poplas-Susič, Irma Rozman Sinur, Tanja Soklič, Katja Triller Vadnal, Nadja Triller, Jure Urbančič, Mihaela Zidarn, 2020, pregledni znanstveni članek

Povzetek: There are large between- and within-country variations in COVID-19 death rates. Some very low death rate settings such as Eastern Asia, Central Europe, the Balkans and Africa have a common feature of eating large quantities of fermented foods whose intake is associated with the activation of the Nrf2 (Nuclear factor (erythroid-derived 2)-like 2) anti-oxidant transcription factor. There are many Nrf2-interacting nutrients (berberine, curcumin, epigallocatechin gallate, genistein, quercetin, resveratrol, sulforaphane) that all act similarly to reduce insulin resistance, endothelial damage, lung injury and cytokine storm. They also act on the same mechanisms (mTOR: Mammalian target of rapamycin, PPAR[gamma]:Peroxisome proliferator-activated receptor, NF[kappa]B: Nuclear factor kappa B, ERK: Extracellular signal-regulated kinases and eIF2[alpha]:Elongation initiation factor 2[alpha]). They may as a result be important in mitigating the severity of COVID-19, acting through the endoplasmic reticulum stress or ACE-Angiotensin-II-AT1R axis (AT1R) pathway. Many Nrf2-interacting nutrients are also interacting with TRPA1 and/or TRPV1. Interestingly, geographical areas with very low COVID-19 mortality are those with the lowest prevalence of obesity (Sub-Saharan Africa and Asia). It is tempting to propose that Nrf2-interacting foods and nutrients can re-balance insulin resistance and have a significant effect on COVID-19 severity. It is therefore possible that the intake of these foods may restore an optimal natural balance for the Nrf2 pathway and may be of interest in the mitigation of COVID-19 severity.
Ključne besede: Covid-19, SARS-CoV-2, food, insulin resistance, obesity, Nrf2, nutrients, TRPA1
Objavljeno v DiRROS: 25.01.2021; Ogledov: 1672; Prenosov: 639
.pdf Celotno besedilo (1,61 MB)

Iskanje izvedeno v 0.3 sek.
Na vrh